Navigation Links
Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
Date:2/10/2017

KNOXVILLE, Tenn., Feb. 10, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it has extended the expiration date of its rights offering to Friday, March 3, 2017 at 5:00 p.m. Eastern Time. All other terms and conditions of the rights offering remain unchanged. 

The units being offered pursuant to the rights offering are being offered under the Company's effective registration statement on Form S-1 (No. 333-213986) by means of a prospectus, as supplemented from time to time, which has been filed with the Securities and Exchange Commission ("SEC") and is available on the website of the SEC at http://www.sec.gov. Electronic copies of the prospectus and prospectus supplements also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3745.  Before you invest, you should read the prospectus, as supplemented from time to time, and other documents Provectus has filed or will file with the SEC for more complete information about Provectus and the rights offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Provectus

Provectus is a clinical-stage biopharmaceutical company developing new therapies for the treatment of solid tumor cancers and dermatologic diseases. Provectus' investigational oncology drug, PV-10, is an oncolytic immunotherapy currently enrolling patients in Phase 3 clinical trials for metastatic melanoma. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug, has completed Phase 2 clinical trials as a treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com or contact Allison + Partners.

FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015, as supplemented by those described in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016) and the following:

  • Provectus' potential receipt of sales from PV-10 and PH-10, transaction fees, licensing and royalty payments; payments in connection with the Company's liquidation, dissolution or winding up, or any sale, lease, conveyance or other disposition of any intellectual property relating to PV-10 or PH-10.
  • our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own;
  • our ability to raise capital through the rights offering; and
  • whether our securities remain listed on the NYSE MKT.

Contact:
Provectus Biopharmaceuticals, Inc.
Timothy C. Scott, President
Phone: 866-594-5999

Allison + Partners
Tom Smith, Managing Director –
Investor Relations
Phone: 646-428-0653

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/provectus-biopharmaceuticals-inc-announces-extension-of-rights-offering-300405855.html


'/>"/>
SOURCE Provectus Biopharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. How These Drug Makers Stocks are Faring? -- Provectus Biopharma, TherapeuticsMD, Novartis, and Tonix Pharma
2. Drug Makers Stocks on Investors Radar -- Provectus Biopharma, Novartis, TherapeuticsMD, and Tonix Pharma
3. Drug Makers Stocks Under Scanner -- Eli Lilly, Provectus Biopharma, GlaxoSmithKline, and Novartis
4. Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders
5. Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD
6. Rodman & Renshaw Initiates Coverage of RegeneRx Biopharmaceuticals, Inc. with Buy Rating
7. Innovate Biopharmaceuticals, Inc. Presenting At Cowen Healthcare Conference Monday, March 7, 2016, And At Future Leaders In The Biotech Industry Friday, March 11, 2016
8. Oxeia Biopharmaceuticals, Inc. Advancing Development Of OXE-103 For The Treatment Of Concussions
9. Global Hyperphosphatemia Drugs Market 2015-2019 with Fresenius Medical Care, Keryx Biopharmaceuticals, Sanofi, Shire & Vifor Pharma Dominating
10. Morgan & Morgan Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. KYTH
11. Harwood Feffer LLP Announces Investigation of Kythera Biopharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... HOUSTON (PRWEB) , ... October 08, 2019 , ... ... compliance (GRC) software as a service (SaaS) platform, today announced integration between the ... reduces the average time it takes medical office staff to obtain peer references ...
(Date:10/8/2019)... ... October 08, 2019 , ... STACS DNA, the sample-tracking ... sexual assault evidence collection kit (SAECK) tracking system. Led by the Executive Office of ... the system is to be implemented in all regions of the state by the ...
(Date:10/8/2019)... ... October 07, 2019 , ... ... Research Institute in a strategic merger to form Apex Innovative Sciences, Inc., an ... central nervous system indications. In the three-company M&A transaction, Apex acquired Clinical Trial ...
Breaking Medicine Technology:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... What unique ... and future state of aging and wellness in the nation? That question will be ... Active Aging Conference, Leadership Summit and Expo. The event will take place October 10-12, ...
(Date:10/8/2019)... CA (PRWEB) , ... October 08, 2019 , ... Dr. ... gum disease in San Jose, CA experience relief from this common and treatable condition. ... in order to save adults from living with uncomfortable symptoms, including tender and bleeding ...
(Date:10/8/2019)... ... October 08, 2019 , ... As ... samples, Meiqing Shi, associate professor with the University of Maryland Department of Veterinary ... published in Nature Communications, Shi and his lab have discovered a new pathway ...
(Date:10/8/2019)... ... October 08, 2019 , ... At the 13th ... President Gregg Church will inform conference attendees how the 4medica Perfect ... starting with the right, clean patient data. The single platform interfaces to core ...
(Date:10/8/2019)... ... October 08, 2019 , ... The University of California San ... Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic category. ... promote faster, better, more cost-effective healthcare by improving outcomes such as shorter hospital ...
Breaking Medicine News(10 mins):